Identification of important interactions between subchondral bone ...

119 Menkes C.J. Radiographic criteria for classification of
osteoarthritis. J Rheumatol Suppl. 1991;27:13-15.
120 Rousseau J.C. and Delmas P.D. Biological markers in
osteoarthritis. Nat Clin Pract Rheumatol. 2007;3(6):346-
356.
121 Fosang A.J., Stanton H., Little C.B., and Atley L.M.
Neoepitopes as biomarkers of cartilage catabolism.
Inflamm Res. 2003;52(7):277-282.
122 Karsdal M.A., Henriksen K., Leeming D.J., Woodworth
T., Vassiliadis E., and Bay-Jensen A.C. Novel
combinations of Post-Translational Modification (PTM)
neo-epitopes provide tissue-specific biochemical markers--
are they the cause or the consequence of the disease? Clin
Biochem. 2010;43(10-11):793-804.
123 Price P.A., Parthemore J.G., and Deftos L.J. New
biochemical marker for bone metabolism. Measurement
by radioimmunoassay of bone GLA protein in the plasma
of normal subjects and patients with bone disease. J Clin
Invest. 1980;66(5):878-883.
124 Mouritzen U., Christgau S., Lehmann H.J., Tanko L.B.,
and Christiansen C. Cartilage turnover assessed with a
newly developed assay measuring collagen type II
degradation products: influence of age, sex, menopause,
hormone replacement therapy, and body mass index. Ann
Rheum Dis. 2003;62(4):332-336.
125 Bonde M., Qvist P., Fledelius C., Riis B.J., and
Christiansen C. Immunoassay for quantifying type I
collagen degradation products in urine evaluated. Clin
Chem. 1994;40(11 Pt 1):2022-2025.
126 Rosenquist C., Fledelius C., Christgau S., Pedersen B.J.,
Bonde M., Qvist P., and Christiansen C. Serum CrossLaps
One Step ELISA. First application of monoclonal
antibodies for measurement in serum of bone-related
degradation products from C-terminal telopeptides of type
I collagen. Clin Chem. 1998;44(11):2281-2289.
127 Schaller S., Henriksen K., Hoegh-Andersen P.,
Sondergaard B.C., Sumer E.U., Tanko L.B., Qvist P. et al.
In vitro, ex vivo, and in vivo methodological approaches
for studying therapeutic targets of osteoporosis and
degenerative joint diseases: how biomarkers can assist?
Assay Drug Dev Technol. 2005;3(5):553-580.
128 Garnero P., Rousseau J.C., and Delmas P.D. Molecular
basis and clinical use of biochemical markers of bone,
cartilage, and synovium in joint diseases. Arthritis Rheum.
2000;43(5):953-968.
CHAPTER 2: Introduction
40
129 Garnero P., Piperno M., Gineyts E., Christgau S., Delmas
P.D., and Vignon E. Cross sectional evaluation of
biochemical markers of bone, cartilage, and synovial tissue
metabolism in patients with knee osteoarthritis: relations
with disease activity and joint damage. Ann Rheum Dis.
2001;60(6):619-626.
130 Bondeson J., Wainwright S., Hughes C., and Caterson B.
The regulation of the ADAMTS4 and ADAMTS5
aggrecanases in osteoarthritis: a review. Clin Exp
Rheumatol. 2008;26(1):139-145.
131 Zhen E.Y., Brittain I.J., Laska D.A., Mitchell P.G., Sumer
E.U., Karsdal M.A., and Duffin K.L. Characterization of
metalloprotease cleavage products of human articular
cartilage. Arthritis Rheum. 2008;58(8):2420-2431.
132 Bay-Jensen A.C., Sondergaard B.C., Christiansen C.,
Karsdal M.A., Madsen S.H., and Qvist P. Biochemical
markers of joint tissue turnover. Assay Drug Dev
Technol. 2010;8(1):118-124.
133 Qvist P., Christiansen C., Karsdal M.A., Madsen S.H.,
Sondergaard B.C., and Bay-Jensen A.C. Application of
biochemical markers in development of drugs for
treatment of osteoarthritis. Biomarkers. 2010;15(1):1-19.
134 Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M.,
Gineyts E., Rosenquist C. et al. Collagen type II C-
telopeptide fragments as an index of cartilage degradation.
Bone. 2001;29(3):209-215.
135 Bay-Jensen A.C., Liu Q., Byrjalsen I., Li Y., Wang J.,
Pedersen C., Leeming D.J. et al. Enzyme-linked
immunosorbent assay (ELISAs) for metalloproteinase
derived type II collagen neoepitope, CIIM--increased
serum CIIM in subjects with severe radiographic
osteoarthritis. Clin Biochem. 2011;44(5-6):423-429.
136 Garnero P., Charni N., Juillet F., Conrozier T., and
Vignon E. Increased urinary type II collagen helical and C
telopeptide levels are independently associated with a
rapidly destructive hip osteoarthritis. Ann Rheum Dis.
2006;65(12):1639-1644.
137 Sondergaard B.C., Henriksen K., Wulf H., Oestergaard S.,
Schurigt U., Brauer R., Danielsen I. et al. Relative
contribution of matrix metalloprotease and cysteine
protease activities to cytokine-stimulated articular cartilage
degradation. Osteoarthritis Cartilage. 2006;14(8):738-748.
138 Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C.,
and Garnero P. A 5-yr longitudinal study of type IIA
collagen synthesis and total type II collagen degradation in
patients with knee osteoarthritis--association with disease
progression. Rheumatology (Oxford). 2007;46(6):938-943.